0001213900-23-081265.txt : 20231010 0001213900-23-081265.hdr.sgml : 20231010 20231010061950 ACCESSION NUMBER: 0001213900-23-081265 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20231009 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231010 DATE AS OF CHANGE: 20231010 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Jasper Therapeutics, Inc. CENTRAL INDEX KEY: 0001788028 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 842984849 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39138 FILM NUMBER: 231315517 BUSINESS ADDRESS: STREET 1: 2200 BRIDGE PKWY SUITE #102 CITY: REDWOOD CITY STATE: CA ZIP: 94065 BUSINESS PHONE: 6505491400 MAIL ADDRESS: STREET 1: 2200 BRIDGE PKWY SUITE #102 CITY: REDWOOD CITY STATE: CA ZIP: 94065 FORMER COMPANY: FORMER CONFORMED NAME: Amplitude Healthcare Acquisition Corp DATE OF NAME CHANGE: 20190912 8-K 1 ea186487-8k_jasper.htm CURRENT REPORT
0001788028 false 0001788028 2023-10-09 2023-10-09 0001788028 JSPR:VotingCommonStockParValue0.0001PerShareMember 2023-10-09 2023-10-09 0001788028 JSPR:RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfVotingCommonStockAtExercisePriceOf11.50Member 2023-10-09 2023-10-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): October 9, 2023

 

 

 

JASPER THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in its Charter)

 

 

 

Delaware   001-39138   84-2984849
(State or Other Jurisdiction
of Incorporation)		   (Commission File Number)   (IRS Employer
Identification No.)

 

2200 Bridge Pkwy Suite #102
Redwood City, California 94065

(Address of Principal Executive Offices) (Zip Code)

 

(650) 549-1400

Registrant’s telephone number, including area code

 

N/A

(Former Name, or Former Address, if Changed Since Last Report)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Exchange Act:

 

(Title of each class)   (Trading Symbol)   (Name of exchange on which registered)
Voting Common Stock, par value $0.0001 per share   JSPR   The Nasdaq Stock Market LLC
Redeemable Warrants, each whole warrant exercisable for one share of Voting Common Stock at an exercise price of $11.50   JSPRW   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 7.01. Regulation FD Disclosure.

 

On October 9, 2023, Jasper Therapeutics, Inc. (the “Company”) issued a press release announcing that its investigational new drug application for a Phase 1b/2a repeat dose clinical study of subcutaneous briquilimab in the treatment of chronic spontaneous urticaria has been cleared by the U.S. Food and Drug Administration. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information in this Item 7.01, including the press release attached hereto as Exhibit 99.1, is being furnished under Item 7.01 of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Description
99.1   Press Release, dated October 9, 2023.
104   Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).

  

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: October 10, 2023 JASPER THERAPEUTICS, INC.
   
  By: /s/ Herb Cross
    Name: Herb Cross
    Title: Chief Financial Officer

 

 

2

 EX-99.1 2 ea186487ex99-1_jasper.htm PRESS RELEASE, DATED OCTOBER 9, 2023

Exhibit 99.1

 

 

Jasper Therapeutics Announces IND Clearance for Phase 1b/2a Study of Subcutaneous Briquilimab in Chronic Spontaneous Urticaria

 

First Patient Expected to be Dosed by Year-end 2023; Early Data Expected by Mid-2024

 

Clinical Study in Chronic Inducible Urticaria Planned to Commence in Early 2024

 

REDWOOD CITY, Calif., October 9, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), as well as lower to intermediate risk myelodysplastic syndromes (LR-MDS) and novel stem cell transplant conditioning regimens, today announced that its investigational new drug (IND) application for a Phase 1b/2a repeat dose clinical study of subcutaneous briquilimab in the treatment of CSU has been cleared by the U.S. Food and Drug Administration (FDA).

 

“We’re very excited to be advancing briquilimab into clinical studies for chronic urticaria patients,” said Edwin Tucker, Chief Medical Officer of Jasper. “The clearance to proceed by the FDA for our IND allows us to move quickly to commence our CSU study in patients who are ineligible for, or refractory to, omalizumab, which is a patient population of high unmet need. We expect this dose escalation study to provide proof of concept for the depletion of mast cells by briquilimab as a differentiated mechanism of action in CSU and to help identify optimal doses and dosing regimens for future registrational studies in the broader CSU patient population.”

 

The Phase 1b/2a study in CSU is a dose escalation study evaluating repeat doses of subcutaneous briquilimab in adult CSU patients who remain symptomatic after treatment with, or who cannot tolerate omalizumab. The study is expected to enroll approximately 40 patients across 6 cohorts and the primary endpoints will be safety and tolerability of briquilimab with secondary endpoints focused on efficacy measures and pharmacokinetics. The study will be conducted at sites in the US and EU and Jasper is expecting to enroll the first patient by the end of 2023 and to be able to report data from early cohorts by mid-2024.

 

“Clearance of the IND for the CSU study is a critical milestone for Jasper, which represents the first step in building out our pipeline with a focus on treating mast cell diseases with briquilimab,” said Ronald Martell, President and Chief Executive Officer of Jasper. “In parallel with our preparations for the CSU study, the team was also developing a proof of concept study in CIndU to further expand our mast cell franchise. A clinical trial application for the CIndU study has now been filed with the European Medicines Agency and we expect to commence the study in the first quarter of 2024, with an initial data read out targeted as early as year-end 2024.”

 

About Briquilimab

 

Briquilimab (formerly JSP191) is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the cell-surface receptor c-Kit, also known as CD117, thereby inhibiting signaling through the receptor. This inhibition disrupts the critical survival signal, leading to the depletion of the mast cells via apoptosis which removes the underlying source of the inflammatory response in mast cell driven disease such as chronic urticaria. Jasper intends to start clinical studies of briquilimab as a primary treatment in Chronic Spontaneous Urticaria as well as in Chronic Inducible Urticaria. Briquilimab is also currently in clinical studies as a treatment for patients with Low to Intermediate Risk myelodysplastic syndromes (MDS) and as a conditioning agent for cell and gene therapies for rare diseases. To date, briquilimab has a demonstrated efficacy and safety profile in more than 145 dosed participants and healthy volunteers, with clinical outcomes as a conditioning agent in severe combined immunodeficiency (SCID), acute myeloid leukemia (AML), MDS, Fanconi anemia (FA), and sickle cell disease (SCD).

 

About Jasper

 

Jasper is a clinical-stage biotechnology company developing briquilimab, a monoclonal antibody targeting c-Kit (CD117) as a therapeutic for chronic mast and stem cell diseases such as chronic urticaria and lower to intermediate risk myelodysplastic syndromes (MDS) and as a conditioning agent for stem cell transplants for rare diseases such as sickle cell disease (SCD), Fanconi anemia (FA) and severe combined immunodeficiency (SCID). To date, briquilimab has a demonstrated efficacy and safety profile in more than 145 dosed participants and healthy volunteers, with clinical outcomes as a conditioning agent in SCID, acute myeloid leukemia (AML), MDS, FA, and SCD. For more information, please visit us at www.jaspertherapeutics.com.

 

 

 

 

Forward-Looking Statements

 

Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding briquilimab’s potential, the development of briquilimab for CSU, LR-MDS and stem cell transplant conditioning; the Phase 1b/2a repeat dose clinical study of subcutaneous briquilimab in the treatment of CSU, including the expected number of patients to be dosed, the cohorts, the site locations and the primary and secondary endpoints; Jasper’s expectations regarding the results of the study, including the potential to provide proof of concept and help identify optimal doses and dosing regimens for future registrational studies; Jasper’s plans to commence a proof of concept study in CIndU, including the expected timing for commencing the study and the expected timing for the initial data read out; briquilimab’s further development and the strategic direction for briquilimab. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of Jasper and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Many actual events and circumstances are beyond the control of Jasper. These forward-looking statements are subject to a number of risks and uncertainties, including general economic, political and business conditions; the risk that the potential product candidates that Jasper develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; the risk that clinical studies or trials may not confirm any safety, potency or other product characteristics described or assumed in this press release; the risk that Jasper will be unable to successfully market or gain market acceptance of its product candidates; the risk that prior study results may not be replicated; the risk that Jasper’s product candidates may not be beneficial to patients or successfully commercialized; patients’ willingness to try new therapies and the willingness of physicians to prescribe these therapies; the effects of competition on Jasper’s business; the risk that third parties on which Jasper depends for laboratory, clinical development, manufacturing and other critical services will fail to perform satisfactorily; the risk that Jasper’s business, operations, clinical development plans and timelines, and supply chain could be adversely affected by the effects of health epidemics; the risk that Jasper will be unable to obtain and maintain sufficient intellectual property protection for its investigational products or will infringe the intellectual property protection of others; and other risks and uncertainties indicated from time to time in Jasper’s filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2022 and any subsequent Quarterly Reports on Form 10-Q. If any of these risks materialize or Jasper’s assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While Jasper may elect to update these forward-looking statements at some point in the future, Jasper specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Jasper’s assessments of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.

 

Contacts:

 

John Mullaly (investors)

LifeSci Advisors

617-429-3548

jmullaly@lifesciadvisors.com

 

Herb Cross (investors)

Jasper Therapeutics

408-621-5925

hcross@jaspertherapeutics.com

 

Lauren Barbiero (media)

Real Chemistry

646-564-2156

lbarbiero@realchemistry.com

 

 

 

 

 GRAPHIC 3 ex99-1_001.jpg GRAPHIC begin 644 ex99-1_001.jpg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end EX-101.SCH 4 jspr-20231009.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 5 jspr-20231009_def.xml XBRL DEFINITION FILE EX-101.LAB 6 jspr-20231009_lab.xml XBRL LABEL FILE Class of Stock [Axis] Voting Common Stock, par value $0.0001 per share Redeemable Warrants, each whole warrant exercisable for one share of Voting Common Stock at an exercise price of $11.50 Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 7 jspr-20231009_pre.xml XBRL PRESENTATION FILE XML 8 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover
Oct. 09, 2023
Document Type 8-K
Amendment Flag false
Document Period End Date Oct. 09, 2023
Entity File Number 001-39138
Entity Registrant Name JASPER THERAPEUTICS, INC.
Entity Central Index Key 0001788028
Entity Tax Identification Number 84-2984849
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 2200 Bridge Pkwy Suite #102
Entity Address, City or Town Redwood City
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94065
City Area Code 650
Local Phone Number 549-1400
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Voting Common Stock, par value $0.0001 per share  
Title of 12(b) Security Voting Common Stock, par value $0.0001 per share
Trading Symbol JSPR
Security Exchange Name NASDAQ
Redeemable Warrants, each whole warrant exercisable for one share of Voting Common Stock at an exercise price of $11.50  
Title of 12(b) Security Redeemable Warrants, each whole warrant exercisable for one share of Voting Common Stock at an exercise price of $11.50
Trading Symbol JSPRW
Security Exchange Name NASDAQ
XML 9 ea186487-8k_jasper_htm.xml IDEA: XBRL DOCUMENT 0001788028 2023-10-09 2023-10-09 0001788028 JSPR:VotingCommonStockParValue0.0001PerShareMember 2023-10-09 2023-10-09 0001788028 JSPR:RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfVotingCommonStockAtExercisePriceOf11.50Member 2023-10-09 2023-10-09 iso4217:USD shares iso4217:USD shares 0001788028 false 8-K 2023-10-09 JASPER THERAPEUTICS, INC. DE 001-39138 84-2984849 2200 Bridge Pkwy Suite #102 Redwood City CA 94065 650 549-1400 false false false false Voting Common Stock, par value $0.0001 per share JSPR NASDAQ Redeemable Warrants, each whole warrant exercisable for one share of Voting Common Stock at an exercise price of $11.50 JSPRW NASDAQ true false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( '@R2E<'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " !X,DI7YARH\NX K @ $0 &1O8U!R;W!S+V-O&ULS9+! M:L,P#(9?9?B>*$[*8";UI:.G#@8K;.QF;+4UBQ-C:R1]^SE>FS*V!QCX8NGW MIT_@5GNAAX#/8? 8R&*\FUS71Z']FIV(O "(^H1.Q3(E^M0\#,$I2M=P!*_T MASHBU%5U#PY)&44*9F#A%R*3K=%"!U0TA O>Z 7O/T.7848#=NBPIPB\Y,#D M/-&?IZZ%&V"&$087OPMH%F*N_HG-'6"7Y!3MDAK'L1R;G$L[<'A[VKWD=0O; M1U*]QO0J6D%GCVMVG?S:;![W6R;KJFX*7J6SYY7@#V*U>I]=?_C=A-U@[,'^ M8^.KH&SAU[^07U!+ P04 " !X,DI7F5R<(Q & "<)P $P 'AL+W1H M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M '@R2E&PO=V]R:W-H965T&UL MQ9AO4^)($,;?WZ>88K>N[JI4DH@*GE*%B+?L'^4 UZI[-R0-F3+)9&@(DZH8.[IOSA20A_?";[IE^)KE82O6H0P##5G&4Z,M&:$QZWFQJ/X28ZR.9 M0H+?S*6*N<%3M6CJ5 $/\J X:GJ.<]J,N4@:W8O\VDAU+V1F(I' 2#&=Q3%7 MSU<0R>5EPVUL+XS%(C3V0K-[D?(%3,##(/+AF.)( +?6 F.'T_0ARBR2LCQ8R/:*'[3 M!KX\WJK?Y(/'P'="R673-F[4Y$/- MHQ%.)+8J$Z/P6X%QIMN73Z NF@:E[(6FOPF[6H=Y.\+N?'/$G,X!\QSO^'5X M$PD*#*_ \'*]XQUZU]+/L-:&39]3J,*AP]N'7PB(XP+BF%3I(4&04]Q$?%%% M0:2!X&@5'*W]DC$")63 !DG L+B5>:&5\C+E=:HKU$G!=D(J#A(CS#.[ M$1&PVRR>54\>6L-QW,/CCGO<)GA."Y[3?7C&L!#:*(Y)N^5Q9:9HG<^]R6@P M9M-/@W%O-+B?#ON3 S:\[1\1C&<%X]D^C'TLJ>(1&R8!K-@7>*ZBI)4<3-U9 MN^UX5.K:!59['ZPI7[%A@&QB+GR>M\K=A:45VZU#K]-NM5L= J]3X'7VP1LF MOE2I5#G9 9L87 A,*M:7&:83LRJ#RG+3XM<#@M!URN;I[,/8"P(%6A]L#]A7 MO(_=)95@-9(>^BF[4B)8 !L]+I_9)!,XX@^NXU'(+_J]^R[DOCW#?$[E,JG$ MI>7&$"PE]B@K0_&51N#2K?PM7U'PD9)/(O&KGS,O9P7[8;A18X/7$HD-(?7+JY?Y4^YF04 MRH0RB!J1DU;GT&TY)%'I$"[=VA^4, 823$P<9\FFQ^E**EJHSM_=TA!BO!HTH>6J66IW0"EV[<(P6'/J8'<'VMMV&X$P+%[N;S'?6C M]6K)2A-PZ4;]$]E0ZPS):@%IV3I K[0 ;R\+&,2@%K:>?Z."">UD2WE2:?$U M@D9E)%G9Z;V:3F^??"!@MQ+K*=F]!F9"8(.5L;D+V!2W2UKDAK_>:%;"TK]1 MF\<7#P!TC_XN\^5@%RD"38ST'P]8RA5[XE$&[*-S9#<_+,6BZY"KZH<$\B?L M ^ZY3KD/EPU\@M6@GJ#1_?V#>^K\10VA] >/[N9387!7+.?,]?Z8_@BEC7BT"^"<"&P9)L_Q3%;VI!J!SY/1F"(I?<2C M+6";/9RO?L@3W WMVMC7"-WV)M>]?RBFTDD\V@!PLP,0\QE6^8$K^[2!NP#@ M?LB6H<2+R_5%!BM0OM#YC7/<]4YU6*G.:3_?_+Z^O,U%:IT=;W1XKAA:P*^:!0BF] MTJ--[1U+AA;:O62:+]XTV;=VW[AU/#)*5^#T.HFJ @ M, P T !X;"]S='EL97,N>&UL[5?;BMLP$/T5H0^HD[@U<4D";2!0:,O" M[D-?E5AV!+JXLIPZ^_756+9S6""QH,FU7-G.-6 M[[S2+^Z-+R RR$_GVC.L+#O/%^_HQ:&_^21[8PMNIS1S.IHV*\E+H&-%=82[ M,W4"H'-&>:$0K#*:]1Q&CT'P80]'16U_+\ M08I**QYJ_^V$FQ4;_*VOZ%9Y6\L*![%LAG="#=A1% MP?6+J??A'=O[Q^%-?+^^X"5KI7N:P#6]R%]X(5J53ZL>8%^&51?Y,YSN>38] MTWPNH0O>\6([J+;:]R+Q@L\Z7.!PC^SZ*XY@/@&+(X!A>3 &F$_PPO+\2_4L MT7H"AG%;1I$EZK-$?8)7#-GV'RQ/W"?W5[S2/$_3+,-V=+N-,MAB^Y9E\(U' MP[B!!Y8',OW97N/=QB?D]3G >OK:A&"5XI.(58KO-2#Q?0.//(]W&\L#'E@7 ML-F!_/$\,%-QGS2%KF+/<^2L;W5'+YC[#Y"5!+ P04 " !X,DI7EXJ[ M', 3 @ "P %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6 M!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV M)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA-/E_G;@2=&A(E@6FD7)TZ(= MI7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0 ( M '@R2E>JQ"(6,P$ "(" / >&PO=V]R:V)O;VLN>&ULC5'1;L(P#/R5 M*A^P%K0A#5%>0-N0I@V-B??0NM0BB2O'A8VOG]NJ&M)>]I31=B;FJ19IZFL:C!VWA'#02=5,3>BD(^IK%AL&6L <2[=)IEL]1;#&:Y M&+6VG-X"$B@$*2C9$7N$2_R==S Y8\0#.I3OW/1W!R;Q&-#C% MB/%*0:S;%4S.Y68R#/; @L4?>M>9_+2'V#-B#Q]6C>1FEJE@A1REW^CUK7H\ M@RX/J!5Z0B? :ROPS-0V&(Z=C*9(;V+T/8SG4.*<_U,C5146L*:B]1!DZ)'! M=09#K+&))@G60VY6= ;N\N@#FW+()FKJIBF>HPYX4P[V1D\E5!B@?%.9J+SV M4VPYZ8Y>9WK_,'G4'EKG5LJ]AU>RY1AQ_)[E#U!+ P04 " !X,DI7)!Z; MHJT #X 0 &@ 'AL+U]R96QS+W=O[IFB MG#S^0W1UW6E\./VR./ /,+Q=Z*E%9"E*%1KD3,)HMC;!4N++3):BJ#(9BBJ6 M<%H@XLD@;6E6?;!/3K3G>1,)KM\,<'AT_@%02P,$% @ >#)* M5V60>9(9 0 SP, !, !;0V]N=&5N=%]4>7!E&ULK9--3L,P$(6O M$F5;)2XL6*"F&V +77 !8T\:J_Z39UK2VS-.VDJ@$A6%3:QXWKS/GI>LWH\1 ML.B=]=B4'5%\% )5!TYB'2)XKK0A.4G\FK8B2K636Q#WR^6#4,$3>*HH>Y3K MU3.T.EY&TWP39G 8ED\C<+,:DH9HS5*$M?%P>L?E.I$J+EST&!G(BY8 M4(JKA%SY'7#J>SM 2D9#L9&)7J5CE>BM0#I:P'K:XLH90]L:!3JHO>.6&F," MJ;$#(&?KT70Q32:>,(S/N]G\P68*R,I-"A$YL01_QYTCR=U59"-(9*:O>"&R M]>S[04Y;@[Z1S>/]#&DWY(%B6.;/^'O&%_\;SO$1PNZ_/[&\UDX:?^:+X3]> M?P%02P$"% ,4 " !X,DI7!T%-8H$ "Q $ @ $ M 9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0 ( '@R2E?F'*CR[@ "L" M 1 " :\ !D;V-097)PC$ 8 )PG 3 " &UL4$L! A0#% @ >#)*5R0"E'@#!0 FA0 !@ M ("!#0@ 'AL+W=O7!E&UL4$L%!@ ) - D /@( ),4 $! end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 3 23 1 false 2 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://jaspertherapeutics.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ea186487-8k_jasper.htm jspr-20231009.xsd jspr-20231009_def.xml jspr-20231009_lab.xml jspr-20231009_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ea186487-8k_jasper.htm": { "nsprefix": "JSPR", "nsuri": "http://jaspertherapeutics.com/20231009", "dts": { "inline": { "local": [ "ea186487-8k_jasper.htm" ] }, "schema": { "local": [ "jspr-20231009.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "definitionLink": { "local": [ "jspr-20231009_def.xml" ] }, "labelLink": { "local": [ "jspr-20231009_lab.xml" ] }, "presentationLink": { "local": [ "jspr-20231009_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 0, "memberCustom": 2, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 3, "entityCount": 1, "segmentCount": 2, "elementCount": 65, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 26 }, "report": { "R1": { "role": "http://jaspertherapeutics.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-10-09", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea186487-8k_jasper.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-10-09", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea186487-8k_jasper.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "JSPR_VotingCommonStockParValue0.0001PerShareMember": { "xbrltype": "domainItemType", "nsuri": "http://jaspertherapeutics.com/20231009", "localname": "VotingCommonStockParValue0.0001PerShareMember", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Voting Common Stock, par value $0.0001 per share" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]" } } }, "auth_ref": [] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "JSPR_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfVotingCommonStockAtExercisePriceOf11.50Member": { "xbrltype": "domainItemType", "nsuri": "http://jaspertherapeutics.com/20231009", "localname": "RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfVotingCommonStockAtExercisePriceOf11.50Member", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Redeemable Warrants, each whole warrant exercisable for one share of Voting Common Stock at an exercise price of $11.50" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://jaspertherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001213900-23-081265-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-23-081265-xbrl.zip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c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end